The global Cancer Biopsy market size is expected to be worth around US$ 32.65 billion by 2028, according to a new report by Vision Research Reports.
The global Cancer Biopsy market size was valued at US$ 19.8 billion in 2020 and is anticipated to grow at a CAGR of 6.35% during forecast period 2021 to 2028.
Several methods of diagnosing cancer patients exist currently, however, biopsy remains to be the only definitive method to confirm the onset of the disease in a patient. Since it involves close examination of organs/tissues, doctors largely rely on biopsies to perform accurate and early diagnosis in susceptible patients.
There has been a significant transition from tumor to which is expected to increase the adoption of kits as well as consumables. Acknowledging this trend, various market players have invested in the development of novel kits in order to expand their biopsy kits portfolio. For instance, Biocept, Inc. recently launched a liquid biopsy kit that is designed for research use pertaining to gene mutations.
Additionally, tumor biopsy is most adopted for the diagnosis on individual levels, along with monitoring the effects of ongoing oncology treatment. Shortcomings of liquid biopsies such as lack of robust efficacy evaluations and their associated high costs are currently bridged by tissue biopsies. This has made tissue biopsy a gold-standard procedure in the present diagnostic scenario.
Moreover, revolutionary advancements in liquid biopsies are expected to be a key factor fueling the overall market growth. Liquid biopsies are expected to offer lucrative opportunities in the field of genomic data analysis and oncology-based personalized medicine. Key players operating in the market such as Cardinal Health; BD; and Biocept, Inc. are focusing on the development of novel or automated biopsies to sustain the current market competition.
Kits and consumables led the market and accounted for over 60.02% share in 2020 as these are integral across various stages of biopsies and robust investments by key players operating in this industry have made significant contributions. This is also supplemented by a considerable increase in the number of patients across the globe that demand instruments and kits to be efficient, accurate, and rapid.
Cancer biopsy has witnessed several developments in terms of instruments, kits, and consumables. With liquid biopsy emerging as a multimodal tool of diagnosis in the field of clinical oncology, the development of efficient products associated with biopsies is pivotal. Though the existing instruments are used predominantly, they are accompanied by various shortcomings. However, the advent of novel technologies is expected to significantly increase the demand for instruments in the coming years.
Several emerging manufacturers are focusing on launching instruments that are able to enhance endoscopy-based biopsies. For instance, BiBBInstruments AB, a Swedish company, has established a strong presence in the instruments market space under the brand - EndoDrill.
The tissue biopsies segment dominated the market and accounted for 86.05% share of the total revenue in 2020. These are still considered to be a mainstay of biopsies and are largely adopted across various cancer diagnosis applications. This is attributed to robust research activities evaluating their safety and efficacy, which has contributed to the segment growth in the global market.
Advancements targeted towards enhancing tissue biopsy procedures are expected to maintain the segment’s lead in the global market for the next few years. For instance, Cernostics is developing an assay suitable for diagnosing cancer patients suffering from Barrett's Esophagus. This one-of-a-kind diagnostic test makes use of biopsy images that are digitally scanned, which aids in the analysis and quantification of alterations occurring at the cellular or molecular levels within a tissue.
Technological developments pertaining to circulating biomarkers detection in blood samples derived from patients allow non-hematologic cancer diagnosis through non-invasive techniques. is considered to be a more practical approach to real-time patient monitoring as compared to conventional tumor biopsies.
Liquid biopsy tests are inclusive of markers such as circulating tumor DNA (ctDNA), (CTCs), and extracellular vesicles (EVs). Exosomes are known to have the ability to alter treatment and manage the dynamics related to disease progression.
The rising preference for liquid biopsy among physicians has been observed in recent years, which is supplemented by its ability to offer disease snapshots from the primary and distant tumor sites. This approach is put to use in personalized medicine treatment, wherein tumor markers are sampled repeatedly to alter the therapy based on the patient’s response to the treatment.
Breast cancer emerged as the dominant segment and accounted for over 14.02% share of the total revenue in 2020. Breast cancer has the largest prevalence rate. Around 1 in 8 U.S. women develop invasive breast cancer as per the U.S. breast cancer statistics. An estimated 276,480 new cases of invasive breast cancer are expected to be diagnosed in women in 2020 in the U.S., along with more than 40,000 new non-invasive breast cancer cases.
Patients suspected of the onset of breast cancer are subjected to microscopic analysis of breast tissue, which is mandatory to obtain a definitive diagnosis along with detecting the stage and characterization of type. This has propelled the demand for a needle biopsy or surgical biopsy to obtain tissue for microscopic analysis, in turn, contributing to the segment growth.
North America held the largest revenue share of over 37.02% in 2020. North America is anticipated to maintain its lead throughout the forecast, with the U.S. making significant contributions to the regional revenue. In addition, distributors and manufacturers operating in this region aim to distribute as well as develop novel kits that are well-suited for rapid diagnostic applications.
Moreover, the increasing adoption of liquid biopsies across the U.S. is largely favored by the profitable strategies laid out by the respective government authorities. Regulatory strategies for liquid biopsy-based oncology diagnostics rely on the framework, which has been developed in recent years by the U.S. Food and Drug Administration (FDA).
BD (Becton, Dickinson And Company)
Thermo Fisher Scientific, Inc.
F. Hoffmann-La Roche Ltd.
Lucence Diagnostics Pte. Ltd.
Exact Sciences Corporation
Freenome Holdings, Inc.
Biodesix (Integrated Diagnostics)
HelioHealth (Laboratory for Advanced Medicine)
Genesystems, Inc. (Genesys Biolabs)
Chronix Biomedical, Inc.
Personal Genome Diagnostics Inc.
Kits and Consumables
Fine Needle Aspiration (FNA)
Core Needle Biopsy (CNB)
Middle East & Africa
The Cancer Biopsy market research report covers definition, classification, product classification, product application, development trend, product technology, competitive landscape, industrial chain structure, industry overview, national policy and planning analysis of the industry, the latest dynamic analysis, etc., and also includes major. The study includes drivers and restraints of the global market. It covers the impact of these drivers and restraints on the demand during the forecast period. The report also highlights opportunities in the market at the global level.
The report provides size (in terms of volume and value) of Cancer Biopsy market for the base year 2020 and the forecast between 2021 and 2028. Market numbers have been estimated based on form and application. Market size and forecast for each application segment have been provided for the global and regional market.
This report focuses on the global Cancer Biopsy market status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Cancer Biopsy market development in United States, Europe and China.
It is pertinent to consider that in a volatile global economy, we haven’t just conducted Cancer Biopsy market forecasts in terms of CAGR, but also studied the market based on key parameters, including Year-on-Year (Y-o-Y) growth, to comprehend the certainty of the market and to find and present the lucrative opportunities in market.
In terms of production side, this report researches the Cancer Biopsy capacity, production, value, ex-factory price, growth rate, market share for major manufacturers, regions (or countries) and type.
In terms of consumption side, this report focuses on the consumption of Cancer Biopsy by regions (countries) and application.
Buyers of the report will have access to verified market figures, including global market size in terms of revenue and volume. As part of production analysis, the authors of the report have provided reliable estimations and calculations for global revenue and volume by Type segment of the global Cancer Biopsy market. These figures have been provided in terms of both revenue and volume for the period 2017 to 2028. Additionally, the report provides accurate figures for production by region in terms of revenue as well as volume for the same period. The report also includes production capacity statistics for the same period.
With regard to production bases and technologies, the research in this report covers the production time, base distribution, technical parameters, research and development trends, technology sources, and sources of raw materials of major Cancer Biopsy market companies.
Regarding the analysis of the industry chain, the research of this report covers the raw materials and equipment of Cancer Biopsy market upstream, downstream customers, marketing channels, industry development trends and investment strategy recommendations. The more specific analysis also includes the main application areas of market and consumption, major regions and Consumption, major Chinese producers, distributors, raw material suppliers, equipment providers and their contact information, industry chain relationship analysis.
The research in this report also includes product parameters, production process, cost structure, and data information classified by region, technology and application. Finally, the paper model new project SWOT analysis and investment feasibility study of the case model.
Overall, this is an in-depth research report specifically for the Cancer Biopsy industry. The research center uses an objective and fair way to conduct an in-depth analysis of the development trend of the industry, providing support and evidence for customer competition analysis, development planning, and investment decision-making. In the course of operation, the project has received support and assistance from technicians and marketing personnel in various links of the industry chain.
The Cancer Biopsy market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies’ focus related to Cancer Biopsy market.
Prominent players in the market are predicted to face tough competition from the new entrants. However, some of the key players are targeting to acquire the startup companies in order to maintain their dominance in the global market. For a detailed analysis of key companies, their strengths, weaknesses, threats, and opportunities are measured in the report by using industry-standard tools such as the SWOT analysis. Regional coverage of key companies is covered in the report to measure their dominance. Key manufacturers of Cancer Biopsy market are focusing on introducing new products to meet the needs of the patrons. The feasibility of new products is also measured by using industry-standard tools.
Key companies are increasing their investments in research and development activities for the discovery of new products. There has also been a rise in the government funding for the introduction of new Cancer Biopsy market. These factors have benefited the growth of the global market for Cancer Biopsy. Going forward, key companies are predicted to benefit from the new product launches and the adoption of technological advancements. Technical advancements have benefited many industries and the global industry is not an exception.
New product launches and the expansion of already existing business are predicted to benefit the key players in maintaining their dominance in the global market for Cancer Biopsy. The global market is segmented on the basis of region, application, en-users and product type. Based on region, the market is divided into North America, Europe, Asia-Pacific, Latin America and Middle East and Africa (MEA).
In this study, the years considered to estimate the market size of Cancer Biopsy are as follows:
Reasons to Purchase this Report:
- Market segmentation analysis including qualitative and quantitative research incorporating the impact of economic and policy aspects
- Regional and country level analysis integrating the demand and supply forces that are influencing the growth of the market.
- Market value USD Million and volume Units Million data for each segment and sub-segment
- Competitive landscape involving the market share of major players, along with the new projects and strategies adopted by players in the past five years
- Comprehensive company profiles covering the product offerings, key financial information, recent developments, SWOT analysis, and strategies employed by the major market players
In-depth interviews and discussions were conducted with several key market participants and opinion leaders to compile the research report.
This research study involved the extensive usage of both primary and secondary data sources. The research process involved the study of various factors affecting the industry, including the government policy, market environment, competitive landscape, historical data, present trends in the market, technological innovation, upcoming technologies and the technical progress in related industry, and market risks, opportunities, market barriers and challenges. The following illustrative figure shows the market research methodology applied in this report.
Market Size Estimation
Top-down and bottom-up approaches are used to estimate and validate the global market size for company, regional division, product type and application (end users).
The market estimations in this report are based on the selling price (excluding any discounts provided by the manufacturer, distributor, wholesaler or traders). Market share analysis, assigned to each of the segments and regions are achieved through product utilization rate and average selling price.
Major manufacturers & their revenues, percentage splits, market shares, growth rates and breakdowns of the product markets are determined through secondary sources and verified through the primary sources.
All possible factors that influence the markets included in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data. The market size for top-level markets and sub-segments is normalized, and the effect of inflation, economic downturns, and regulatory & policy changes or others factors are accounted for in the market forecast. This data is combined and added with detailed inputs and analysis from Vision Research Reports and presented in this report.
Market Breakdown and Data Triangulation
After complete market engineering with calculations for market statistics; market size estimations; market forecasting; market breakdown; and data triangulation. Extensive primary research was conducted to gather information and verify and validate the critical numbers arrived at. In the complete market engineering process, both top-down and bottom-up approaches were extensively used, along with several data triangulation methods, to perform market estimation and market forecasting for the overall market segments and sub-segments listed in this report.
Secondary Sources occupies approximately 25% of data sources, such as press releases, annual reports, Non-Profit organizations, industry associations, governmental agencies and customs data, and so on. This research study includes secondary sources; directories; databases such as Bloomberg Business, Wind Info, Hoovers, Factiva (Dow Jones & Company), TRADING ECONOMICS, and avention; Investing News Network; statista; Federal Reserve Economic Data; annual reports; investor presentations; and SEC filings of companies.
In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side include product manufacturers (and their competitors), opinion leaders, industry experts, research institutions, distributors, dealer and traders, as well as the raw materials suppliers and producers, etc.
The primary sources from the demand side include industry experts such as business leaders, marketing and sales directors, technology and innovation directors, supply chain executive, end users (product buyers), and related key executives from various key companies and organizations operating in the global market.
The study objectives of this report are:
MicroRNA Market Size, Share, Trends, Growth, Production, Consumption, Revenue, Company Analysis and Forecast 2021-2030Read more...
Medical Devices Reimbursement Market Size, Share, Trends, Growth, Production, Consumption, Revenue, Company Analysis and Forecast 2021-2030Read more...
Advanced Wound Care Market Size, Share, Trends, Growth, Production, Consumption, Revenue, Company Analysis and Forecast 2021-2030Read more...
Ambulance Services Market Size, Share, Trends, Growth, Production, Consumption, Revenue, Company Analysis and Forecast 2021-2030Read more...
Prosthetics & Orthotics Market Size, Share, Trends, Growth, Production, Consumption, Revenue, Company Analysis and Forecast 2021-2030Read more...